Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. - Wikidata - awgldk - TriplyDB

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

http://www.wikidata.org/entity/Q36058502

about

Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers The development of immunoconjugates for targeted cancer therapy Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer Advances in anticancer immunotoxin therapy Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor Mechanisms of action of therapeutic antibodies for cancer Novel CD20 monoclonal antibodies for lymphoma therapy Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins.Removing T-cell epitopes with computational protein design.Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.Pediatric Rhabdomyosarcoma.Targeted diphtheria toxin to treat BPDCN.In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer.An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.Antibody phage display libraries: contributions to oncology.Update on the biology and treatment options for hairy cell leukemia.Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.Characterization of CD22 expression in acute lymphoblastic leukemia Construction, expression, and characterization of a recombinant immunotoxin targeting EpCAM.Advances in phage display technology for drug discovery.Improving access to novel agents for childhood leukemia.Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A.A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products Impact of telomere length on survival in classic and variant hairy cell leukemia.Immunoconjugates in the management of hairy cell leukemia.

P2860

Q26751473-690C905F-3108-4EAC-A6B3-95EEDDEF1DB9 Q27021990-DD0BD294-C5D4-4E82-990C-7C769984C49A Q28077270-46DC149A-1331-4682-9186-E52947FEB85F Q28085551-B7D7EFB6-72A6-4F05-BC60-CE3BCE27FF30 Q28266122-3065B476-D17B-43A4-9202-16B037611FD8 Q28385366-944A5F76-F90E-479F-B520-97BBFE6B35ED Q28390112-39AFA599-588A-4200-878C-6D76018D084D Q28553712-BEC327D0-BB0B-4E79-ABE5-F1CFE95CBD38 Q30362724-317CF7CC-6860-46D3-BD8B-853B6619696D Q33410756-351C6145-EF43-4ACC-B391-78B2D5880BC0 Q33415933-33EB6050-4C2A-4459-A773-5E2A79FE25A5 Q33652098-1D12224B-8BA1-4F9D-960D-D48A87DA1547 Q33761496-1BC5D4F3-EF26-42F1-A48B-341A89FCBDEC Q33767727-E632F034-7CC9-4D66-9F5A-D72A3C9C8FAD Q33840201-349C0976-2038-4C3E-A25C-3B8F62A87132 Q33842070-12CB693D-7E4B-46DB-B1F8-B1CFD024C176 Q33917153-4C72A145-DB98-4A8A-BF4F-83EFEDBB4700 Q34080906-116D2021-357F-4CA6-95DE-018A291F4B9A Q34276680-28896CD7-BA8A-4589-ACA4-92B88DB5D199 Q34323838-024CDC4C-EEF7-452A-A8A8-4A2EB5C8FFC2 Q34323991-3BE6ADDC-4430-43F8-BDB2-F3EE97F728B2 Q34343369-CD9A1F15-8EB6-4EDE-8997-839911A53D54 Q34385892-E7F1ABD4-5E21-400D-8F0E-533D5259CD51 Q34387911-42F92755-5211-4408-A278-62656649E84A Q34459015-3102293C-4DE7-47BF-85F6-1B0AD600011B Q34459751-AEA5AE3D-38D7-409C-8A76-358445E76A3B Q35070412-97F5B803-CFC8-4027-8FC8-9B3618A4124E Q35180101-3E0F981F-1590-487B-B0F4-F1FBCE1FDF6D Q35514128-E4861220-12E1-4F6D-88F6-7F1ECFB2B79C Q35556641-9A193CAC-3229-4AEC-A710-987D15594464 Q35614190-EE185091-F87C-47E7-BE4D-003940ECB064 Q35688742-4F9261C0-E6BF-4449-A04B-EDFF5E23439B Q35876956-F632168C-934F-49CA-B8AB-15273D8BE3C8 Q35992503-F178BBED-500A-4241-9748-93B33349B44A Q36069886-EB1B5AFC-AE10-4A48-BFCE-B81E329C2B46 Q36157120-94AF8742-C792-47F7-AFB8-6DF50D65DED4 Q36269852-D82B9D01-F266-4352-8D28-C18542CABAB8 Q36273796-D9F07C52-9248-4E83-9918-79EC449E9373 Q36322450-CD91631F-2E72-4B82-A22B-F355082F87EB Q36328016-6089C240-FCEF-41C5-97A9-5843A0F96DB3

P2860

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

http://www.wikidata.org/entity/Q36058502

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Phase I trial of anti-CD22 rec ...... ents with hairy cell leukemia.

@ast

Phase I trial of anti-CD22 rec ...... ents with hairy cell leukemia.

@en

type

label

Phase I trial of anti-CD22 rec ...... ents with hairy cell leukemia.

@ast

Phase I trial of anti-CD22 rec ...... ents with hairy cell leukemia.

@en

prefLabel

Phase I trial of anti-CD22 rec ...... ents with hairy cell leukemia.

@ast

Phase I trial of anti-CD22 rec ...... ents with hairy cell leukemia.

@en

P1433

Q36058502-00985C64-27F6-4546-9454-E4A9361054CD

P1476

Q36058502-7BB799DB-44ED-4F9F-AC60-6B0CC3F678D2

P2093

Q36058502-0DBD2716-5440-4F6D-96B2-954E6D48A139

Q36058502-12D5C253-B3BF-4CB5-8CA4-7B83713607D7

Q36058502-202F893F-56CD-4185-8ED0-A7AD8444ABC6

Q36058502-8A25C7AB-2933-4300-B5C8-DF5D8DC4372D

Q36058502-9340394D-2E97-42A0-B741-91095C162769

Q36058502-9CFD046B-C732-4F55-A00B-1A78EAA585AF

Q36058502-A2D4539B-EB15-468D-B3A1-A8FEEAD88B24

Q36058502-DF42DD7F-2A51-4FEE-9C43-FCE306BEBD01

P2860

Q36058502-05DB6062-B153-4356-A24B-60A60EA6B30A

Q36058502-07721759-8E10-464F-A2FB-48959EE7B520

Q36058502-0BED3803-89F2-47A1-BEF6-C08F5B1E24F7

Q36058502-206932C4-8B8F-4E45-B54B-6C0FA92B381E

Q36058502-3DABECFA-5AA8-43B0-9788-01A392BF05F7

Q36058502-40A6D1DF-10A3-4F28-8AD8-31ECA23E86A2

Q36058502-53133FFC-C76F-404C-940A-91D937246A57

Q36058502-58468663-9390-4DE0-9482-745BD881C704

Q36058502-6411BF0F-6EC8-44FF-9410-3674C4AF12B1

Q36058502-6C79354D-C859-48DA-8CC2-305F6C7728E3

P304

Q36058502-221659E5-D5C3-4CBE-B163-4A795CAF2797

P31

Q36058502-15AB5620-EBE1-48C5-A1E7-B0D9BDE1D0AE

P356

Q36058502-ECC3EE88-39F0-454D-8E6D-BC101D516017

P407

Q36058502-475BAC2D-627B-4BEB-974D-4408D6D7C969

P433

Q36058502-BA6A3E68-80E9-4CFA-8C53-ED13D0A0408E

P478

Q36058502-685DAD45-C412-4E82-B756-A85DFDE6E676

P50

Q36058502-BA6E64C5-364A-4FA6-A77B-D224736A85B6

P577

Q36058502-EC6F2FE7-2474-4B13-80F4-07BB8C78A2C3

P698

Q36058502-C09E5828-3E15-4663-A78F-4F69A7B06438

P921

Q36058502-145BBC61-589A-488A-81CB-72B49FE86896

Q36058502-A65FABD8-BDE3-4BA6-AC51-E93BAACB708C

P932

Q36058502-9349E513-3644-443F-B478-208D9234A057

P356

JCO.2011.38.1756

P1433

Journal of Clinical Oncology

P1476

Phase I trial of anti-CD22 rec ...... ents with hairy cell leukemia.

@en

P2093

David J Fitzgerald

http://www.w3.org/2001/XMLSchema#string

Ira Pastan

http://www.w3.org/2001/XMLSchema#string

Maryalice Stetler-Stevenson

http://www.w3.org/2001/XMLSchema#string

Robert J Kreitman

http://www.w3.org/2001/XMLSchema#string

Robert Lechleider

http://www.w3.org/2001/XMLSchema#string

Steven Coutre

http://www.w3.org/2001/XMLSchema#string

Tadeusz Robak

http://www.w3.org/2001/XMLSchema#string

Wyndham H Wilson

http://www.w3.org/2001/XMLSchema#string

P2860

Thrombotic microangiopathy with targeted cancer agents

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.

Pentostatin: impact on outcome in hairy cell leukemia.

Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.

Hairy cell leukemia: towards a curative strategy.

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.

P304

1822-1828

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.38.1756

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Martin S Tallman

P577

2012-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22355053

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

3383181

http://www.w3.org/2001/XMLSchema#string